A carboxylated maltodextrin gallium complex

By preparing carboxylated maltodextrin gallium complex, the limitations of vancomycin in the treatment of MRSA infection were overcome, providing a new treatment option, especially effective against vancomycin-resistant strains, achieving both antibacterial and histopathological improvement of MRSA infection.

CN123106933APending Publication Date: 2026-11-17BEIJING FENGRUI PHARM TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611261025.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2026-05-12
Filing Date
2026-08-19
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing vancomycin treatments for MRSA infection have limitations due to nephrotoxicity, ototoxicity, limited tissue penetration, and drug resistance.

Method used

A carboxylated maltodextrin-gallium complex was developed. The complex is prepared by a one-pot process using gallium ions and carboxylated maltodextrin ligands to form a water-soluble solid powder for use in combination with existing antibacterial drugs to combat MRSA infection.

Benefits of technology

Carboxylated maltodextrin gallium complex has shown antibacterial activity against MRSA infection and improved lung tissue pathology, providing a new treatment option for MRSA infection, especially effective against vancomycin-resistant strains.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106933A_ABST
    Figure CN123106933A_ABST
Patent Text Reader

Abstract

This application relates to the field of medicinal chemistry, disclosing a carboxylated maltodextrin complex, its preparation method, and its applications. The carboxylated maltodextrin complex is obtained by oxidation with sodium hypochlorite to obtain a carboxylated intermediate, followed by alkali curing, acid curing, and high-temperature curing with gallium chloride. The compound is characterized by a combination of infrared and ultraviolet absorption spectroscopy. This compound can be used to prepare drugs for treating drug-resistant bacterial infections, especially methicillin-resistant Staphylococcus aureus (MRSA) infections; it can also be used in combination with existing drugs to reverse bacterial resistance. This application also discloses corresponding preparation examples, analytical detection methods, and in vivo efficacy results in mouse pneumonia.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This application relates to the fields of medicinal chemistry, preparation of sugar-metal complexes and pharmaceutical applications, specifically to a carboxylated maltodextrin gallium complex, its preparation method, analytical characterization method, and its application in drug-resistant infection-related applications. Background Technology

[0002] Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most common multidrug-resistant pathogens in clinical practice. Since its first report in 1961, MRSA has expanded from hospital-acquired infections (HA-MRSA) to community-acquired infections (CA-MRSA), posing a serious threat to global public health. MRSA can cause a variety of serious infectious diseases, including pneumonia, bloodstream infections, skin and soft tissue infections, and bone and joint infections, and is particularly challenging to manage in intensive care units (ICUs).

[0003] Currently, vancomycin is one of the standard clinical drugs for treating severe MRSA infections. Vancomycin is a glycopeptide antibiotic that exerts its bactericidal effect by inhibiting the cross-linking of peptidoglycan in bacterial cell walls. However, vancomycin has the following limitations in clinical use: (1) nephrotoxicity and ototoxicity: its therapeutic window is narrow, and therapeutic drug monitoring (TDM) is often required in clinical practice to balance efficacy and toxicity; (2) limited tissue penetration: its distribution in lung tissue is poor, and its therapeutic effect on MRSA pneumonia is not ideal; (3) the emergence of drug resistance: vancomycin-intermediate resistant Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) have emerged, which limits the available treatment options for this type of severe infection. The above limitations indicate that there is a clear clinical need to develop anti-MRSA drugs with new mechanisms of action. Summary of the Invention

[0004] The first objective of this application is to provide a carboxylated maltodextrin gallium complex. This invention establishes a basis for compound identification through joint characterization using gallium content, characteristic peaks in infrared spectroscopy, and ultraviolet absorption data.

[0005] The second objective of this application is to provide a method for preparing the aforementioned carboxylated maltodextrin gallium complex. This method is based on a one-pot process, completing oxidation, coordination, alkali curing, high-temperature curing, acid curing, and purification processes without separating intermediates. The process route is clear and easily scaled up.

[0006] A third objective of this application is to provide the use of the aforementioned carboxy-maltodextrin gallium complex in drug-resistant bacterial infections, particularly in methicillin-resistant Staphylococcus aureus (MRSA) infections, and further to cover its use in combination with existing antimicrobial drugs to address bacterial resistance.

[0007] To achieve the above objectives, the present invention provides a carboxylated maltodextrin gallium complex, wherein the ligand is carboxylated maltodextrin, and the gallium in the complex exists in the form of trivalent gallium ions and is linked to the carboxyl group and / or hydroxyl group on the ligand through coordinate bonds; the gallium content in the complex is determined by ultraviolet-visible spectrophotometry to be 5% to 30% (mass percentage), preferably 18.6% to 24.5%.

[0008] The aforementioned carboxylated maltodextrin gallium complex exhibits characteristic absorption peaks in its infrared spectrum at the following wavenumbers: 3382 cm⁻¹, 2930 cm⁻¹, 1646 cm⁻¹, 1157 cm⁻¹, 1081 cm⁻¹, and 1022 cm⁻¹. Furthermore, its UV-Vis spectrum shows strong terminal absorption at 195.5 nm and weak absorption at 258.5 nm.

[0009] The above-mentioned carboxy-maltodextrin gallium complex has a weight-average molecular weight (Mw) of 5,000–50,000 Da, determined by gel permeation chromatography.

[0010] The aforementioned carboxylated maltodextrin gallium complex is a water-soluble product.

[0011] The aforementioned carboxylated maltodextrin gallium complex, when detected by size exclusion high-performance liquid chromatography, exhibits a chromatographic pattern of a single main peak plus a broad diffuse peak at the rear end; the complex is a solid powder.

[0012] Another object of the present invention is to provide a carboxylated maltodextrin gallium complex, wherein the ligand is carboxylated maltodextrin, and the gallium in the complex exists in the form of trivalent gallium ions and is linked to the carboxyl group and / or hydroxyl group on the ligand through coordinate bonds; the gallium content in the complex is determined to be 5%~30% (mass percentage) by ultraviolet-visible spectrophotometry; its infrared spectrum has characteristic absorption peaks at 3382 cm⁻¹, 2930 cm⁻¹, 1646 cm⁻¹, 1157 cm⁻¹, 1081 cm⁻¹ and 1022 cm⁻¹; its ultraviolet-visible spectrum shows strong terminal absorption at 195.5 nm and weak absorption at 258.5 nm; its weight-average molecular weight (Mw) is 5,000–50,000 Da, determined by gel permeation chromatography.

[0013] The aforementioned carboxylated maltodextrin gallium complex is a water-soluble product.

[0014] The aforementioned carboxylated maltodextrin gallium complex exhibits a chromatographic pattern of a single main peak plus a broad diffuse peak at the rear end when detected by size exclusion high-performance liquid chromatography; the complex is a solid powder.

[0015] The polydispersity index (PDI) (Mw / Mn) of the above-mentioned carboxy-based maltodextrin gallium complex is 1.5–3.0.

[0016] The aforementioned carboxy-maltodextrin gallium complex also exhibits absorption peaks in the fingerprint region at 1459 cm⁻¹, 1417 cm⁻¹, 1381 cm⁻¹, 1306 cm⁻¹, 1238 cm⁻¹, 931 cm⁻¹, 849 cm⁻¹, 762 cm⁻¹, 712 cm⁻¹, 608 cm⁻¹, 574 cm⁻¹, and 525 cm⁻¹.

[0017] This invention provides a method for preparing the above-mentioned carboxylated maltodextrin gallium complex, comprising the following steps:

[0018] (1) Using maltodextrin as the starting material, sodium hypochlorite was used for oxidation under alkaline conditions, and sodium bromide was used as a catalyst to obtain a carboxylated maltodextrin solution.

[0019] (2) Add gallium source to the solution obtained in step (1), first add 20% (w / w) sodium carbonate aqueous solution to the system with an initial pH of 1.1–1.3, adjust the pH to 1.5–2.5, then add sodium hydroxide aqueous solution to adjust the system to the pH of 10–12 at the alkali curing endpoint, and carry out alkali curing at 40–55 °C;

[0020] (3) After alkali curing, the product is not separated, but directly refluxed at 97–101 °C for 30–60 minutes for high-temperature curing;

[0021] (4) Add anhydrous ethanol to precipitate the product, filter and dry at 40–50 °C to obtain crude product;

[0022] (5) After dissolving the crude product in purified water, adjust the pH to 5.0–7.0 with 30% dilute hydrochloric acid, centrifuge and take the supernatant, then add anhydrous ethanol to crystallize, filter and dry at 40–60 °C for 48 hours to obtain the carboxy-maltodextrin gallium complex product.

[0023] In the above preparation method, step (5) further includes at least one of the cooling and / or washing steps.

[0024] In the above preparation method, the amount of sodium bromide used is 0.005-0.015 times the amount of maltodextrin added.

[0025] In the above preparation method, the pH of the alkali curing endpoint in step (2) is 10.5–11, and the pH of the acid curing in step (5) is 5.0–7.0.

[0026] The preparation method described above further includes at least one of the cooling and / or washing steps in step (5).

[0027] The present invention provides a pharmaceutical composition comprising a therapeutically effective amount of the above-mentioned carboxy-maltodextrin gallium complex, and at least one pharmaceutically acceptable carrier and / or excipient.

[0028] The above-mentioned pharmaceutical composition is in the form of an injection, an oral preparation, or a topical preparation.

[0029] The above-described pharmaceutical composition, wherein the injection is an intravenous injection, wherein the carboxy-maltodextrin gallium complex is present in aqueous solution at a concentration of 10–100 mg / mL.

[0030] This invention provides the use of the above-described carboxylated maltodextrin gallium complex or the above-described pharmaceutical composition in the preparation of a medicament for treating drug-resistant bacterial infections.

[0031] In the above applications, the drug-resistant bacteria are methicillin-resistant Staphylococcus aureus (MRSA).

[0032] In the above applications, the infection is pneumonia, bloodstream infection, skin and soft tissue infection, or bone and joint infection caused by MRSA.

[0033] In the above application, the infection is pneumonia caused by MRSA.

[0034] In the above applications, the drug can be administered intravenously.

[0035] In the above applications, the MRSA is a Staphylococcus aureus strain that is reduced in sensitivity to vancomycin (VISA) or resistant to it (VRSA).

[0036] This invention provides an analytical method for determining the gallium content in the above-mentioned carboxylated maltodextrin gallium complex. The method employs ultraviolet-visible spectrophotometry, using butylrhodamine B as the colorimetric reagent, measuring the absorbance at a detection wavelength of 565 nm, and calculating the gallium content based on a standard curve. This analytical method is used to determine the gallium content in the carboxylated maltodextrin gallium complex of claim 1.

[0037] The present invention also provides an analytical method for determining the content of carboxy-maltodextrin ligands (calculated as glucose) in the above-mentioned carboxy-maltodextrin gallium complex, wherein the determination is performed by high performance liquid chromatography (HPLC).

[0038] Chromatographic conditions: A strong cation exchange column (MORHCH TECHNOLOGIES Itolsep CAM Ca2+ 8% 7.8 × 300 mm, 8 μm) filled with sulfonated crosslinked styrene-divinylbenzene copolymer was used with water as the mobile phase; isocratic elution was performed; the flow rate was 0.5 mL / min; the column temperature was 80 °C; a differential refractive index detector was used with a detection cell temperature of 35 °C; and the injection volume was 20 μL.

[0039] Test sample determination: Accurately weigh approximately 500 mg of this product and place it in a 250 ml stoppered conical flask. Add 25 ml of 20% hydrochloric acid solution, heat in a water bath for 30 minutes, cool, and transfer the entire solution to a 100 ml beaker. Adjust the pH to 6.0 with 10% sodium hydroxide solution, transfer the entire solution to a 100 ml volumetric flask, dilute to the mark with water, shake well, and filter through a 0.45 μm PTFE filter membrane. Inject the filtrate into the liquid chromatograph and record the chromatogram. Calculate the ligand content in the test sample using a calibration curve established with glucose standard.

[0040] The present invention also provides an analytical method for the content of carboxy maltodextrin ligands in the above-mentioned carboxy maltodextrin gallium complex, characterized in that high performance liquid chromatography (HPLC) is used to determine the content of carboxy maltodextrin ligands (calculated as glucose) in the complex;

[0041] Chromatographic conditions: Strong cation calcium exchange column used; mobile phase was appropriate concentration of salt buffer; detector was differential refractive index detector; flow rate 0.5–1.0 mL / min;

[0042] Test sample determination: Accurately weigh approximately 500 mg of this product and place it in a 250 ml stoppered conical flask. Add 25 ml of 20% hydrochloric acid solution, heat in a water bath for 30 minutes, cool, and transfer the entire solution to a 100 ml beaker. Adjust the pH to 6.0 with 10% sodium hydroxide solution, transfer the entire solution to a 100 ml volumetric flask, dilute to the mark with water, shake well, filter through a 0.45 μm PTFE membrane, collect the filtrate, filter through a 0.22-0.45 μm microporous membrane, and inject it into the liquid chromatograph. Record the chromatogram. Calculate the ligand content in the test sample using a calibration curve established with carboxymaltodextrin (calculated as glucose) standard.

[0043] Compared with the prior art, this application uses a combination of gallium content, infrared spectral characteristic peaks, and ultraviolet absorption data to characterize the carboxylated maltodextrin gallium complex, giving the compound claims a clear spectral identification basis; the preparation process parameters fully cover oxidation, alkali curing, high-temperature curing, acid curing, crystallization, and drying steps; based on the in vivo efficacy experiment results of acute pneumonia in mice, the complex showed antibacterial effect and lung tissue pathological improvement effect on the MRSA infection model, providing experimental evidence for its application in the treatment of drug-resistant infections. Attached Figure Description

[0044] Figure 1 The image shows the infrared spectrum of the target compound.

[0045] Figure 2 This is the UV-Vis absorption spectrum of the target compound.

[0046] Figure 3 The bar chart shows the bacterial load in the lungs of each group of animals in the first preliminary experiment.

[0047] Figure 4 The bar chart shows the pathological scores of lung tissue in each group of animals during the first preliminary experiment.

[0048] Figure 5 The bar chart shows the bacterial load in the lungs of each group of animals in the second preliminary experiment. Detailed Implementation

[0049] The present application will be further described below with reference to embodiments and accompanying drawings. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of protection of the present application. Unless otherwise specified, the experimental conditions, test conditions, and processing methods described herein are based on the original descriptions in the provided technical disclosure and research reports, without any modification to the original experimental data.

[0050] Example 1 Preparation of the target compound

[0051] Maltodextrin was used as the starting material, oxidized with sodium hypochlorite under alkaline conditions, and sodium bromide was used as a catalyst. The amount of sodium bromide was 0.005-0.015 times the amount of maltodextrin, to obtain a carboxylated maltodextrin solution. The reducing sugar equivalent (DE value) of the maltodextrin used was controlled within the range of 10–15.

[0052] In alkali curing of gallium-containing systems, the initial system pH is 1.1–1.3. A 20% (w / w) sodium carbonate aqueous solution is added dropwise to adjust the pH to 1.5–2.5; subsequently, a sodium hydroxide aqueous solution is added dropwise to adjust the system to the final pH of 10.5. The alkali curing temperature is controlled at 40–55 °C, and the pH value is continuously monitored using an online pH meter. This stepwise alkali addition method helps avoid the formation of gallium hydroxide precipitation caused by direct use of sodium hydroxide, thus promoting the formation of the target gallium core complex structure. Mechanical stirring is used during the alkali curing process.

[0053] After alkali curing, the product is not separated, but directly refluxed in a water bath at 97–101 °C for 30–60 minutes for high-temperature curing. Anhydrous ethanol is then added to the system as a poor solvent to precipitate the water-soluble product. After filtration, the product is dried at 40–50 °C to obtain the crude target compound. The crude product is dissolved in purified water at 5 times its mass, and the pH is adjusted to 5.0–7.0 with 30% dilute hydrochloric acid. After centrifugation, the supernatant is collected, and anhydrous ethanol is added to induce crystallization. The crystals are then filtered to obtain the wet product. Finally, the product is dried at 40–60 °C for 48 hours to obtain the final target compound. Based on 100 g of maltodextrin, the yield of the final target compound is 90.3–110.1%.

[0054] Example 2 Preparation of the target compound

[0055] Example 2 illustrates a variation within the lower limit range of preparation parameters: except for the following conditions, the remaining steps are the same as in Example 1. In the alkali curing stage, the system pH was first adjusted from 1.1–1.3 to 1.5, and then further adjusted to the final pH of 10.0, with alkali curing performed at 40 °C; the high-temperature curing temperature was 97 °C, refluxed for 30 minutes; in the acid curing stage, the pH was adjusted to 5.0; finally, the product was dried at 40 °C for 48 hours. This example demonstrates that the target compound can still be obtained within the lower limit range of the process parameters in this application. Based on 100 g of maltodextrin, the yield of the target compound is 84.5–90.5%.

[0056] Example 3 Preparation of the target compound

[0057] Example 3 is a variation of the preferred process window: except for the following conditions, the remaining steps are the same as in Example 1. In the alkali curing stage, the system pH is first adjusted to 2.0, then to the final pH of 10.5, and alkali curing is performed at 45 °C; the high-temperature curing temperature is 99 °C, and reflux is carried out for 45 minutes; in the acid curing stage, the pH is adjusted to 6.0; finally, the product is dried at 50 °C for 48 hours. This example is used to illustrate the preferred process window of this application. Based on 100 g of maltodextrin, the yield of the target compound is 85.0–92.0%.

[0058] Example 4 Preparation of the target compound

[0059] Example 4 illustrates a variation of the upper limit process parameters: except for the following conditions, the remaining steps are the same as in Example 1. In the alkali curing stage, the system pH is first adjusted to 2.5, then to the final pH of 11.0, and alkali curing is performed at 55 °C; the high-temperature curing temperature is 101 °C, and reflux is carried out for 60 minutes; in the acid curing stage, the pH is adjusted to 7.0; finally, the product is dried at 60 °C for 48 hours. This example is used to illustrate the upper limit process parameter conditions. Based on 100 g of maltodextrin, the yield of the target compound is 84.3–87.3%.

[0060] Example 5 Preparation and purification of the target compound

[0061] Example 5 is a summary example of the purification and drying parameter range: except for the following conditions, the remaining steps are the same as in Example 1. Five times the mass of purified water is used for dissolving the crude product; the pH for acid solidification is controlled within the range of 5.0–7.0; after centrifugal purification, the supernatant is collected and then crystallized with anhydrous ethanol to obtain the wet product; finally, it is dried at a low temperature of 40–60 °C for 48 hours to avoid damaging the product structure. This example is used to summarize the purification and drying parameter range of this application. Based on 100 g of maltodextrin, the yield of the target compound is 80.2–84.6%.

[0062] Example 6 Infrared Spectroscopic Characterization

[0063] Fourier transform infrared spectroscopy (FT-IR) was used to determine the infrared spectra of the carboxylated maltodextrin gallium complex sample prepared in Example 1 using the potassium bromide (KBr) pellet method. Measurement conditions: scanning range 4000–400 cm⁻¹; sample scans 16 times; background scans 16 times; resolution 3.814 cm⁻¹.

[0064] The results are as follows Figure 1 As shown, the infrared spectrum of the carboxylated maltodextrin gallium complex exhibits characteristic absorption peaks at the following wavenumbers:

[0065] 3382 cm⁻¹ (strong, broad, O–H hydroxyl stretching vibration); 2930 cm⁻¹ (medium, C–H methylene–CH₂– stretching vibration); 1646 cm⁻¹ (strong, COO antisymmetric stretching vibration, characteristic peak of gallium trivalent ion coordination); 1157 cm⁻¹ (strong, C–O–C asymmetric stretching vibration, polysaccharide backbone); 1081 cm⁻¹ (strong, C–O secondary alcohol stretching vibration); 1022 cm⁻¹ (strong, C–O primary alcohol stretching vibration).

[0066] In addition, a series of absorption peaks were observed in the fingerprint region, including 1459, 1417, 1381, 1306, 1238, 931, 849, 762, 712, 608, 574, and 525 cm⁻¹. These infrared characteristic peaks collectively constitute the infrared fingerprint spectrum of the carboxyl maltodextrin gallium complex. Among them, the COO antisymmetric stretching vibration peak at 1646 cm⁻¹ can serve as an infrared characterization of the interaction between the carboxyl group and trivalent gallium.

[0067] Example 7 Ultraviolet Spectroscopic Characterization

[0068] An appropriate amount of the carboxy-maltodextrin gallium complex prepared in Example 1 was used as a solvent (purified water was used as the solvent, with a baseline of approximately zero absorption in the blank solvent) to prepare a test solution (1 mg) of appropriate concentration. A full-wavelength scan was performed using a UV-Vis spectrophotometer (instrument model: Shimadzu UV-2600, S / N: A11665532782). Measurement conditions: scan range 190–800 nm; medium scan speed; sampling interval 0.5 nm; slit width 2.0 nm; integration time 0.1 seconds.

[0069] The results are as follows Figure 2 As shown, the UV-Vis spectrum of the aqueous solution of carboxy-maltodextrin gallium complex exhibits the following characteristic absorptions: 195.5 nm (absorbance Abs=2.430, strong end absorption); 258.5 nm (Abs=0.129, weak absorption peak); 251.0 nm (Abs=0.129, peak valley).

[0070] Example 8: Gallium Content Determination

[0071] This embodiment employs ultraviolet-visible spectrophotometry, using butyl rhodamine B as the chromogenic reagent, to determine the gallium content in carboxy-maltodextrin gallium complexes. Establishment of the standard curve: An appropriate amount of gallium standard was accurately weighed, dissolved in dilute hydrochloric acid, and diluted to volume to prepare a series of standard solutions with known gallium concentrations. In an acidic medium, butyl rhodamine B was added to each standard solution, and trivalent gallium ions formed a colored complex with butyl rhodamine B. Using the corresponding reagent blank as a reference, the absorbance of each standard solution was measured at a detection wavelength of 565 nm. A standard curve was plotted with gallium concentration (μg / mL) on the x-axis and absorbance on the y-axis to obtain the regression equation.

[0072] Test sample determination: Accurately weigh an appropriate amount of the carboxylated maltodextrin gallium complex test sample prepared in Examples 1-5. After appropriate digestion (acid hydrolysis, gallium ion ionization) pretreatment, operate according to the standard curve method described above, and measure the absorbance of the test sample solution at 565 nm. Substitute the absorbance into the regression equation to calculate the gallium content. Test results: The gallium content (by mass percentage) of three batches of carboxylated maltodextrin gallium complex test samples was determined according to the above method. The gallium content was all within the range of 18.6% to 24.5%, indicating that this method can be used to determine the gallium content in the batches of test samples under the stated conditions.

[0073] Example 9 Determination of Dextrin Content

[0074] The content of carboxymaltodextrin ligands in carboxymaltodextrin gallium complexes was determined by high performance liquid chromatography (HPLC). Chromatographic conditions: a strong cation exchange column (MORHCH TECHNOLOGIES Itolsep CAM Ca2+ 8% 7.8 × 300 mm, 8 μm) packed with sulfonated crosslinked styrene-divinylbenzene copolymer was used, with water as the mobile phase; isocratic elution; flow rate of 0.5 mL / min; column temperature of 80 °C; differential refractive index detector with a detector cell temperature of 35 °C; injection volume of 20 μL.

[0075] Test sample determination: Accurately weigh approximately 500 mg of the carboxy-maltodextrin gallium complex test sample prepared in Examples 1-5, place it in a 250 ml stoppered conical flask, add 25 ml of 20% hydrochloric acid solution, heat in a water bath for 30 minutes, cool, and transfer the entire solution to a 100 ml beaker. Adjust the pH to 6.0 with 10% sodium hydroxide solution, transfer the entire solution to a 100 ml volumetric flask, dilute to the mark with water, shake well, filter through a 0.45 μm PTFE filter membrane, and collect the filtrate. Inject into a liquid chromatograph and record the chromatogram. Calculate the ligand content in the test sample using a calibration curve established with glucose standard. Results: The ligand content (calculated as glucose) in the carboxy-maltodextrin gallium complex test sample is complementary to the gallium content, and their sum accounts for 85%–98% of the total mass of the complex. The remainder is water and a small amount of residual inorganic salts.

[0076] Example 10 Determination of molecular weight by gel permeation chromatography (GPC)

[0077] The weight-average molecular weight (Mw) and molecular weight distribution of carboxy-maltodextrin gallium complexes were determined by gel permeation chromatography (GPC). The determination conditions were as follows: a high-performance liquid chromatography system equipped with a gel chromatography column (tandem) of appropriate pore size; a salt buffer of appropriate concentration as the mobile phase; a column temperature of 45 °C; a refractive index detector (RID) at 45 °C; and a flow rate of 0.5 mL / min.

[0078] Test sample determination: Accurately weigh an appropriate amount of the carboxy-maltodextrin gallium complex test sample prepared in Example 1, dissolve it in 0.1 mol / L sodium hydroxide solution, dilute it with the mobile phase to prepare a solution with a concentration of 0.4-0.6 mg / mL, filter it through a 0.22 μm microporous membrane, and then inject the sample. The column was calibrated using pullulan standard with a known molecular weight. Results: The weight-average molecular weight (Mw) of the carboxy-maltodextrin gallium complex was in the range of 5,000–50,000 Da, and the polydispersity index (PDI, Mw / Mn) was 1.5–3.0.

[0079] Experimental Example: In vivo drug efficacy pre-experiment in mice with acute pneumonia

[0080] Experimental animals: Twelve female 6–7 week old SPF-grade Balb / c mice were used for the first and second preliminary experiments. All animals were purchased from qualified laboratory animal suppliers. After a 7-day quarantine and acclimatization period upon arrival, the corresponding experiments began.

[0081] Environmental conditions: The experimental environment temperature was 20–26 ℃, and the humidity was 40–70%. The light cycle was controlled as a 12-hour / 12-hour light-dark cycle.

[0082] Pathogenic microorganism: Methicillin-resistant Staphylococcus aureus (S. aureus, strain number ATCC33591=BNCC326053, purchased from a qualified strain preservation institution), hereinafter abbreviated as MRSA.

[0083] Test drug: The test drug (20 mg / mL) was provided by the client (Example 1). Vancomycin hydrochloride was provided by a qualified supplier.

[0084] (I) First Preliminary Experiment Scheme

[0085] Table 1. Detailed grouping information of animals in the first preliminary experiment.

[0086] Grouping describe quantity Vaccination Dosage A Model group 4 MRSA / B Low-dose group of target compound 4 MRSA 10 mg / kg C High-dose group of target compounds 4 MRSA 100 mg / kg

[0087] Establishing an acute pneumonia model: Animals were acclimatized after quarantine before the experiment was conducted. Anesthesia was performed using a small animal gas anesthesia machine (ABS, Shanghai Yuyan Scientific Instruments Co., Ltd.). MRSA was inoculated intranasally at a volume of 25 μL, 1×10⁻⁶ g / L. 8 CFU / mL / each.

[0088] Administration: Animals were administered the drug 4 hours after inoculation via tail vein injection (IV), once daily (qd), for 3 consecutive days. Group A received saline, Group B received 2 mg / mL of the target compound (diluted 10-fold with saline), and Group C received 20 mg / mL of the test drug, all in 0.1 mL volumes.

[0089] Detection indicators: Animals were sacrificed 24 hours after the last administration, and a lobe of the right lung was collected, weighed, homogenized, and used for bacterial counting. The left lung was also collected, fixed, and stained with H&E for histopathological analysis.

[0090] (II) Second Preliminary Experiment Scheme

[0091] Table 2. Detailed grouping information of animals in the second preliminary experiment.

[0092] Grouping describe quantity Vaccination Dosage A Model group 3 MRSA / B Positive control group 3 MRSA 60 mg / kg C target compound group 3 MRSA 500 mg / kg D Target compound + positive drug combination group 3 MRSA 100+60 mg / kg

[0093] Establishing an acute pneumonia model: Animals were acclimatized after quarantine before the experiment was conducted. Anesthesia was performed using a small animal gas anesthesia machine (ABS, Shanghai Yuyan Scientific Instruments Co., Ltd.). MRSA was inoculated intranasally at a volume of 25 μL, 5 × 10⁻⁶ g / L. 8 CFU / mL / each.

[0094] Administration: Animals were administered medication via tail vein injection (IV) 4 hours after inoculation, once daily (qd) for 3 consecutive days. Group A received saline; Group B received 2.4 mg / mL vancomycin hydrochloride (0.5 mL); Group C received 20 mg / mL test drug (0.5 mL); and Group D received 20 + 12 mg / mL test drug (0.5 + 0.1 = 0.6 mL; the drugs were mixed before injection).

[0095] Detection indicators: Animals were sacrificed 24 hours after the last administration, and one lobe of the right lung was collected, homogenized with 1 mL of physiological saline, and counted for bacteria. The left lung was also collected, fixed, and stained with H&E for histopathological analysis.

[0096] (III) Experimental Results

[0097] Table 3 Results of Lung Bacterial Load in the First Preliminary Experiment

[0098] Group Dosage (mg / kg) Bacterial load (right lung, CFU / mL, Mean±SD) Inhibition rate (%) A Physiological saline solution ( / ) 13325±2735 0 B Target compound (10) 7000±2126 47.47 C Target compound (100) 3835±2133 71.22

[0099] Table 4. Results of lung tissue pathological analysis in the first preliminary experiment.

[0100] Group Dosage (mg / kg) Inflammation level Alveolar interstitial thickening Total Score A Physiological saline solution ( / ) 2.50±0.58 2.75±0.50 5.25±0.96 B Target compound (10) 1.00±1.15 2.00±0.00 3.00±1.15 C Target compound (100) 0.00±0.00 0.50±1.00 0.50±1.00

[0101] Table 5 Results of Lung Bacterial Load in the Second Preliminary Experiment

[0102] Group Dosage Bacterial load (right lung, CFU / mL, Mean±SD) Inhibition rate (%) A / 377667±138511 0 B Vancomycin hydrochloride (60) 228900±127493 39.39 C Target compound (500) 122333±38682 67.61 D Target compound + vancomycin hydrochloride (100 + 60) 155667±19629 58.78

[0103] Summary: At a dose of 10 mg / kg, the target compound inhibited 47.47% of the bacteria, with slight improvement in tissue lesions; at a dose of 100 mg / kg, the inhibition rate was 71.22%, with significant improvement in tissue lesions; and at a dose of 500 mg / kg, the inhibition rate was 67.61%. Due to differences in the modeling concentration, dosage, and sample size in the two preliminary experiments, the current results only show the trend of antibacterial activity and pathological improvement under the listed experimental conditions. The inhibition rate was 58.78% when the target compound was used in combination with vancomycin hydrochloride (100 + 60 mg / kg).

[0104] Application in drug-resistant infections: Based on the preliminary experimental results of the mouse acute pneumonia animal model, the carboxylated maltodextrin gallium complex provides a basis for the preparation of a drug for treating pneumonia caused by MRSA. This application does not use the aforementioned preliminary experiments as evidence for its application in VISA, VRSA, or in synergy with vancomycin.

Claims

1. A carboxylated maltodextrin gallium complex, wherein the ligand is carboxylated maltodextrin, and the gallium in the complex exists in the form of trivalent gallium ions and is linked to the carboxyl group and / or hydroxyl group on the ligand through coordinate bonds; the gallium content in the complex is determined to be 5% to 30% (mass percentage) by ultraviolet-visible spectrophotometry.

2. The carboxylated maltodextrin gallium complex according to claim 1, characterized in that, Its infrared spectrum has characteristic absorption peaks at the following wavenumbers: 3382 cm⁻¹, 2930 cm⁻¹, 1646 cm⁻¹, 1157 cm⁻¹, 1081 cm⁻¹, and 1022 cm⁻¹.

3. The carboxylated maltodextrin gallium complex according to claim 1, characterized in that, Its ultraviolet-visible spectrum shows strong terminal absorption at 195.5 nm and weak absorption at 258.5 nm.

4. The carboxylated maltodextrin gallium complex according to any one of claims 1 to 3, characterized in that, Its weight-average molecular weight (Mw) is 5,000–50,000 Da, determined by gel permeation chromatography.

5. The carboxylated maltodextrin gallium complex according to claim 1, characterized in that, The complex is a water-soluble product.

6. The carboxylated maltodextrin gallium complex according to any one of claims 1 to 4, characterized in that, When the complex is detected by size exclusion high performance liquid chromatography, it exhibits a chromatographic pattern of a single main peak plus a broad diffuse peak at the rear end; the complex is a solid powder.

7. A method for preparing the carboxylated maltodextrin gallium complex according to any one of claims 1 to 6, characterized in that, Includes the following steps: (1) Using maltodextrin as the starting material, sodium hypochlorite was used for oxidation under alkaline conditions, and sodium bromide was used as a catalyst to obtain a carboxylated maltodextrin solution. (2) Add gallium source to the solution obtained in step (1), first add 20% (w / w) sodium carbonate aqueous solution to the system with an initial pH of 1.1–1.3 to adjust the pH to 1.5–2.5, then add sodium hydroxide aqueous solution to adjust the system to the pH of 10–12 at the end point of alkali curing, and carry out alkali curing at 40–55 °C; (3) After alkali curing, the product is not separated, but directly refluxed at 97–101 °C for 30–60 minutes for high-temperature curing; (4) Add anhydrous ethanol to precipitate the product, filter and dry at 40–50 °C to obtain crude product; (5) After dissolving the crude product in purified water, adjust the pH to 5.0–7.0 with 30% dilute hydrochloric acid, centrifuge and take the supernatant, then add anhydrous ethanol to crystallize, filter and dry at 40–60 °C for 48 hours to obtain the carboxy-maltodextrin gallium complex product.

8. The preparation method according to claim 7, characterized in that, The amount of sodium bromide used is 0.005-0.015 times the amount of maltodextrin added.

9. The preparation method according to claim 7, characterized in that, In step (2), the pH of the alkali curing endpoint is 10.5–11, and in step (5), the pH of the acid curing endpoint is 5.0–7.

0.

10. The preparation method according to claim 7, characterized in that, Step (5) also includes at least one of the cooling and / or washing steps.

11. A pharmaceutical composition, characterized in that, The product comprises a therapeutically effective amount of any one of claims 1 to 6, and at least one pharmaceutically acceptable carrier and / or excipient.

12. The use of the carboxylated maltodextrin gallium complex of any one of claims 1 to 6 or the pharmaceutical composition of claim 11 in the preparation of a medicament for treating drug-resistant bacterial infections.

13. The application according to claim 12, characterized in that, The drug-resistant bacteria is methicillin-resistant Staphylococcus aureus (MRSA).

14. An analytical method for determining the content of carboxylated maltodextrin ligands in the carboxylated maltodextrin gallium complex according to any one of claims 1 to 6, characterized in that, The content of carboxylated maltodextrin ligands (calculated as glucose) in the complex was determined by high performance liquid chromatography (HPLC). Chromatographic conditions: Strong cation calcium exchange column used; mobile phase was appropriate concentration of salt buffer; detector was differential refractive index detector; flow rate 0.5–1.0 mL / min; Test sample determination: Accurately weigh approximately 500 mg of this product and place it in a 250 ml stoppered conical flask. Add 25 ml of 20% hydrochloric acid solution, heat in a water bath for 30 minutes, cool, and transfer the entire solution to a 100 ml beaker. Adjust the pH to 6.0 with 10% sodium hydroxide solution, transfer the entire solution to a 100 ml volumetric flask, dilute to the mark with water, shake well, filter through a 0.45 μm PTFE membrane, collect the filtrate, filter through a 0.22-0.45 μm microporous membrane, and inject it into the liquid chromatograph. Record the chromatogram. Calculate the ligand content in the test sample using a calibration curve established with carboxymaltodextrin (calculated as glucose) standard.